Aim immunotech to present at the h.c. wainwright 24th annual global investment conference

Ocala, fla., sept. 07, 2022 (globe newswire) -- aim immunotech inc. (nyse: american aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including covid-19, the disease caused by the sars-cov-2 virus, today announced that thomas k. equels, m.s. j.d. chief executive officer of aim, will present at the virtual h.c. wainwright 24 th annual global investment conference being held in new york, n.y., and virtually, september 12-14, 2022.
AIM Ratings Summary
AIM Quant Ranking